LDX

2.27%

4.5¢ lumos diagnostics holdings limited

@bariscan90 this is the short write up that I did on MeMed back...

First 79 Last

Share
Profile

Follow
LongTony

2,647 Posts.

2395

19/11/22

23:50

Post #: 64875205
Share

Originally posted by LongTony: ↑

I think this is the report from the FDA around their review (approval) of the MeMed BV test. The development of the test was partly funded by the US government.

https://www.accessdata.fda.gov/cdrh_docs/reviews/K210254.pdf

At the top of page 4 of the report they outline the results you get from the "machine that goes 'bing!'" 15 minutes after the sample is taken - the text is pasted as an image below. Apparently, according to the review, the test is very reliable and repeatable. However, it's very equivocal when it comes to viral/bacterial/nothing diagnosis, in fact so equivocal to my mind that IMHO it is useless!

As you can see with the score ranges, the MeMed test really creates very little certainty around what to do. A physician or other health professional can run the test, everybody pockets their rebates and they can then prescribe antibiotics for any score from 35 to 100, or maybe even even between 10 to 100. Who knows? And it takes so long (ie 15 minutes, which is longer than a standard appointment) that they'll only do the test if they really have to.

It's a win-win-win! The physician can say they've been diligent, the physician gets extra money, MeMed gets money, and the physician can still prescribe just as many antibiotics as ever, so pharma still gets their money.

When I first had the opportunity to invest in this, I asked Sam if the "industry" in the US was ready for FebriDx and he said the feedback was yes. But looking at the approval for MeMed BV and the knock-back of FebriDx, I'd say it's clear that they're not ready for a line on a piece of paper that says "Don't prescribe $4B US a year in un-necessary antibiotics."

I'd say there's still a big push needed to get the FDA, with its impure architecture, to approve FebriDx, because FebriDx puts a clear line through $4B of Pharma revenue, and although the US says they want to stop, their are too many people riding on that gravy train.

Expand

@bariscan90 this is the short write up that I did on MeMed back in July, as you can see it's an excellent test, it gives absolutely useless results so that you can claim for the test and still prescribe anti-biotics.

It's a bona fide win-win for the medical industry (unfortunately it's a lose-lose for patients and the fight against over prescription of anti-biotics).

LDX Price at posting: 5.8¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Bitcoin investors need to know the risks

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

There are more pages in this discussion • 2 more messages in this thread...

First 79 Last

Add LDX (ASX) to my watchlist

(20min delay)
Last 4.5¢		Change 0.001(2.27%)		Mkt cap ! $21.65M

Open	High	Low	Value	Volume
4.3¢	4.5¢	4.3¢	$53.65K	1.227M

Buyers (Bids)

No.	Vol.	Price($)
4	445618	4.3¢

Sellers (Offers)

Price($)	Vol.	No.
4.6¢	600000	2

View Market Depth

No.	Vol.	Price($)
4	445618	0.043
4	639826	0.042
2	292500	0.041
2	280001	0.040
1	360000	0.039

Price($)	Vol.	No.
0.046	600000	2
0.048	218015	3
0.049	200000	1
0.050	200000	1
0.052	100000	1

Last trade - 16.10pm 12/07/2024 (20 minute delay)

LDX (ASX) Chart

@bariscan90 this is the short write up that I did on MeMed back...

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Immutep reports strong response rate from immunotherapies treating carcinomas

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Bitcoin investors need to know the risks

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

@bariscan90 this is the short write up that I did on MeMed back...

Top Stories

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Immutep reports strong response rate from immunotherapies treating carcinomas

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Bitcoin investors need to know the risks

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News